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ABSTRACT
The BMT program at Princess Margaret Hospital performed 105 transplants using cryopreserved peripheral
blood stem cells (PBSC) from related allogeneic donors. The outcomes were compared with those of a historic
control of 106 patients transplanted with freshly procured PBSC. The infusions were tolerated with limited
toxicity related to nausea/vomiting or bradycardia, correlated with the total amount of DMSO infused. The
average viability of the total nucleated cell (TNC) population after thawing was 71%. The survival of
clonogenic progenitors amounted to 75% for colony-forming unit-granulocyte-macrophage (CFU-GM), 69%
for burst-forming units erythroid (BFU-E), and 78% for colony-forming units granulocyte-erythrocyte-
monocyte-megakaryocyte (CFU-GEMM). In contrast, colony-forming units megakaryocyte (CFU-MEG) was
significantly more cryosensitive with recovery rates of 39%. The number of viable CD34 cells transplanted
was correlated with the number of transplanted viable CFU-GM (P < .001), BFU-E (P < .001), CFU-MEG
(P< .001), and CFU-GEMM (P .049), but not with the TNC dose. The number of transplanted CD34 cells
was correlated with engraftment of neutrophils (P  .012) and platelets (P  .013). The outcomes of
cryopreseved or fresh PBSC transplants (PBSCT) with respect to engraftment of neutrophils (P  .178) and
platelets (P  .785), lymphocyte recovery (P  .926), acute (P  .113), and chronic graft-versus-host disease
(P  .673), recurrence (P  .295), nonrelapse mortality (P  .340), and overall survival (P  .668) were not
significantly different. It is therefore reasonable to consider the option of cryopreserved allografts.
© 2007 American Society for Blood and Marrow Transplantation
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ﬂNTRODUCTION
The efﬁcacy of cryopreserved hematopoietic pro-
enitor cells is well established for blood and marrow-
erived autografts [1-4]. Despite some toxicities re-
ated to dimethylsulfoxide (DMSO) [5-7] and high cell
umbers [8], the procedure has an excellent safety
ecord [9-12]. Although the experience with cryopre-
erved allografts is limited [13,14], the technology is
sed predominantly to store umbilical cord blood [15].
n addition, there is a recent trend to use cryopre-
erved grafts obtained from unrelated donors [13,16]. dheoretical concerns over cryopreserving allografts
nclude the possibility of damaging selective cell pop-
lations, particularly T cells, that may reduce the
ntitumor effect of cryopreserved grafts, contamina-
ion of grafts secondary to the more extensive manip-
lation, and toxicity related to the use of DMSO as
ryoprotectant. On the other hand, cryopreserved al-
ografts may enhance the safety by guaranteeing the
vailability of a quality controlled graft prior to initi-
ting myeloablative therapies, and may increase the
exibility of scheduling transplants. These issues were
iscussed in a recent review [16] suggesting that there
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D. H. Kim et al.1234re insufﬁcient data available to recommend the use of
resh allografts over cryopreserved preparations.
It was the objective of the current study to gain the
ecessary information and develop recommendations by
omparing the safety and clinical outcomes of a series of
ryopreserved peripheral blood derived (PBSC) consec-
tive allografts with that of a historic control series of
reshly procured PBSC. Secondary objectives included
mpact assessment of cryopreservation on the survival of
lonogenic hematopoietic progenitors and their contri-
ution to engraftment as well as lymphocyte recovery
fter transplantation.
ETHODS AND MATERIALS
ranulocyte-colony stimulating factor (G-CSF)
obilized PBSC Collections from Healthy Donors
A total of 105 consecutive recipients of cryopre-
erved allogeneic PBSC transplants (PBSCT) col-
ected from related donors between September 2003
nd December 2005 were included in a prospective
tudy. These represented all patients with hematopoi-
tic malignancies who received transplants with PBSC
rom a related donor during the indicated time inter-
al. One hundred six consecutive patients with hema-
opoietic malignancies transplanted with freshly col-
ected PBSC between June 2001 and August 2003
erved as a historic control. The characteristic features
f recipients and donors of both cohorts are summa-
ized in Table 1. All donors were screened for risk
actors and medically examined before commence-
ent of G-CSF injections. The evaluation included a
one marrow study. The marrow samples of all do-
ors in this study were morphologically normal. Writ-
en consents were obtained from both recipients and
onors.
All donors were mobilized with subcutaneous in-
ections of G-CSF (Neupogen®, Amgen Canada,
ississauga, Canada) at a dose of 10 g/kg/day. G-
SF was routinely administered for 4 consecutive days
rior to the PBSC collection on day 5. The minimum
arget of CD34 cells was deﬁned as 4 106/kg actual
eight of the recipient. Provisions were made for
dditional injections of G-CSF and collections if the
arget number was not obtained on the ﬁrst day of
ollection. The apheresis procedure was performed
ith a COBE Spectra cell separator (Gambro BCT,
akewood, CO) using acid-citrate-dextrose formula A
ACD-A) as anticoagulant as well as 2000 units of
eparin. The median blood volume processed during
collection was 18 L (range: 7.7-53.3 L).
ryopreservation, Thawing, and Infusion of
llogeneic PBSCs
PBSC products were prepared in a cell-processing
aboratory under current good manufacturing stan- tards. Cells were cryopreserved at total nucleated cell
TNC) concentrations of 3  108/mL using 10%
MSO as the cryoprotectant, and where necessary,
sing autologous plasma and/or plasmalyte as a di-
uent [17-20]. The products were placed in 86°C
reezer for a minimum of 3 hours and a maximum of
days before being moved into the vapor phase of a
iquid nitrogen freezer for long-term storage.
Grafts were thawed at bedside by immersing the
ryobags into a 40°C water bath. Viability was as-
essed via trypan blue exclusion.The thawed PBSC
roducts were infused within 10-15 minutes through a
entral venous catheter without ﬁltration. All patients
eceived 20 mg of dexamethasone, 25 mg of meperi-
ine, 50 mg of diphenhydramine, and 1 mg of gran-
setron intravenously, and 2 mg of lorazepam sublin-
ually 30 minutes prior to infusion. Heavy meals were
voided for 3 to 4 hours prior to infusion.
linical Transplant Procedures
The transplant procedure and posttransplant man-
gement followed previously described institutional pol-
cies [21-24]. They are summarized in Table 1. The
linical data were updated as of July 2006, and in-
luded the following events: engraftment of neutro-
hils, platelets, and lymphocytes, acute and chronic
raft-versus-host disease (aGVHD, cGVHD), recur-
ence of disease, nonrelapse mortality (NRM), and
verall survival (OS). Absolute lymphocyte counts
ALCs) were recorded at 1, 2, 3, 6, 9, 12, 18, 24, and
6 months after PBSCT.
uantification of CD34 Cells by Flow Cytometry
nd Clonogenic Hematopoietic Progenitor
ells in Culture
Each PBSC product was evaluated before cryo-
reservation to determine the number of TNCs and
D34 cells, as well as the presence and frequency of
ulticolony-forming units granulocyte-erythrocyte-
onocyte-megakaryocyte (CFU-GEMM) and single
CFU-GM, Burst-forming units erythroid (BFU-E),
nd colony-forming units megakaryocyte (CFU-
EG)] lineage clonogenic hematopoietic progenitors.
fter thawing, each PBSC product was assessed by
rypan blue exclusion for viability of TNCs. The data
ere used to calculate the number of infused viable
D34 cells. The content of viable clonogenic pro-
enitors was quantiﬁed in culture as well as calculated
sing the trypan blue data. As described previously,
lonogenic progenitor cells were assessed by growing
 104 TNCs for 14 days in semisolid methylcellu-
ose cultures [8,9]. CD34 cell counts were obtained
y ﬂow cytometry on fresh cells before cryopreserva-
ion [25,26].
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Allogeneic PBSCT with Cryopreserved Grafts 1235able 1. Properties of Patients, Donors, Grafts, and Transplant Procedures for Both Cohorts Receiving Either Cryopreserved or Freshly Procured
BSCT
Cryopreserved PBSCT (n  105) Fresh PBSCT (n  106) P-Value
ecipients
Sex (F/M) 48/57 (46%/54%) 46/69 (43%/57%) NS
Age (years) 51 (17-71) 49 (21-69) NS
Weight (kg, mean  SE) 73.5  1.4 71.2  1.9
iseases NS
AML/ALL 42/7 (40%/7%) 44/14 (42%/13%)
MDS/MF 7/9 (7%/8%) 9/1 (8%/1%)
CML/CLL 9/15 (8%/14%) 15/7 (14%/7%)
NHL/HD 13/1 (12%/1%) 12/1 (11%/1%)
MM/solid 2/0 (2%/0%) 1/2 (1%/2%)
onors
Sex (F/M) 50/55 (48%/52%) 65/41 (61%/39%) NS
Age (years) 47 (12-75) 48.5 (13-73) NS
Weight (kg, mean  SE) 74.5  1.8 73.9  2.0 NS
MV status (R/D, n  193) NS
(pos/pos)/(pos/neg) 44/11 (44%11%) 41/10 (44%/11%)
(neg/pos)/(neg/neg) 20/25 (20%/25%) 19/23 (20%/25%)
BSC collection
1-/2-/>3 times 90/12/3 (86%/11%/3%) 79/24/3 (75%/23%/3%) NS
ransplant CD34 cell dose
CD34 cells (106/kg) 4.8 (2.3-14.8) 5.2 (1.7-13.4)
CD34 cells, > 5  106/kg 41 (45%) 43 (54%) NS
FUs, infused (104/kg)
CFU-GM
(mean  SE) 134.87  8.44 132.86  16.12 NS
(median, range) 118.67 (8.95-451.75) 108.76 (5.12-1111.81)
BFU-E
(mean  SE) 141.19  7.73 126.38  12.53 NS
(median, range) 134.02 (4.41-350.70) 112.56 (1.40-942.18)
CFU-MEG
(mean  SE) 24.11  2.27 42.28  6.37 .009
(median, range) 19.68 (0-86.16) 32.75 (0.47-475.70)
CFU-GEMM
(mean  SE) 8.77  0.46 4.63  0.35 <.001
(median, range) 8.39 (0-21.04) 2.65 (0.47-20.28)
onditioning regimen NS
Myeloablative 74 (70%) 79 (74%)
TBI based/non-TBI based 47/27 (45%/26%) 65/14 (61%/13%)
Reduced intensity 31 (30%) 27 (26%)
VHD prophylaxis NS
CSA/MTX 62 (59%) 74 (70%)
CSA/MMF 31 (29%) 26 (24%)
Others* 12 (12%) 5 (5%)
ype of PBSCT NS
Syngeneic 3 (3%) 1 (1%)
Allogeneic sibling 98 (93%) 94 (89%)
Allogeneic family 4 (4%) 11 (10%)
LA-disparity NS
HLA-identical 95 (91%) 93 (88%)
1-antigen mismatched 10 (9%) 13 (12%)
BSCT indicates peripheral blood stem cell transplantation; F, female; M, male; SE, standard error; AML, acute myelogenous leukemia; ALL,
acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MF, myeloﬁbrosis; CML, chronic myelogenous leukemia; CLL, chronic
lymphocytic leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; CMV, cytomegalovirus; R,
recipient; D, donor; pos, positive; neg, negative; PBSC, peripheral blood stem cells; CFUs, colony-forming units; CFU-GM, colony-
forming units granulocyte-macrophage; BFU-E, Burst-forming units erythroid; CFU-MEG, colony-forming units megakaryocyte; CFU-
GEMM, colony-forming units granulocyte-erythrocyte-monocyte-megakaryocyte; TBI, total body irradiation; CSA, cyclosporine A;
MTX, methotrexate; MMF, mycophenolate mofetil; HLA, human leukocyte antigen.
Others included cyclosporine alone (n  4 in cryopreserved PBSCT and n  5 in fresh PBSCT group), FK506 with mycophenolate mofetil
or methotrexate (n  4 in cryopreserved PBSCT and n  1 in fresh PBSCT group), and others (experimental ATG prophylaxis protocol,
n  4 in cryopreserved PBSCT group).
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D. H. Kim et al.1236efinitions
The day of the PBSC infusion was deﬁned as day
. Engraftment was determined as a peripheral abso-
ute neutrophil count (ANC) of 0.5  109/L for 2
onsecutive days, and a peripheral platelet count of
20  109/L for at least 3 consecutive days without
equiring transfusion. aGVHD and cGVHD were di-
gnosed and graded using established criteria [27,28].
S was deﬁned as the time from transplantation until
eath from any cause. NRM was deﬁned as death not
elated to disease recurrence or progression. The in-
idence of recurrence was deﬁned as the time from
ransplantation until disease progression. The disease
isk of the recipients was deﬁned as low, intermediate,
nd high, as previously described [29].
tatistics
Clinical characteristics of patients transplanted
ith cryopreserved or fresh PBSC were compared by
isher’s exact or Mann-Whitney’s U-test. The OS,
ncidence of engraftment, GVHD, NRM, and recur-
ence were assessed by log rank test. A logistic regres-
ion analysis was performed to evaluate the effect of
arious parameters on the occurrence of infusion-
elated toxicity using a forward conditional procedure
5,8]. These parameters included sex and body weight
f recipients, TNCs infused, volume of DMSO, and
he interval between PBSC collection and infusion.
The relationship of TNCs, CD34 cells, CFU-
M, BFU-E, CFU-MEG, and CFU-GEMM within
ach graft was evaluated by applying the Pearson’s
orrelation test. The inﬂuence of each cell subset on
eutrophil and platelet engraftment was assessed by
reating each subset as categoric variable deﬁned as
ither above or below the median. A Cox’s propor-
ional hazard regression model was used to test pa-
ameters for their independence. Lymphocyte counts
ere determined serially and compared for both co-
orts at 1, 2, 3, 6, 9, 12, 18, 24, and 36 months after
BSCT using a general linear model based on serial
ata.
The contribution of potential prognostic factors
o OS, NRM, and recurrence were examined by uni-
nd multivariate analyses of parameters identiﬁed by
ox’s proportional hazard regression. They included
he following variables: cryopreservation (fresh versus
ryopreserved PBSCT), conditioning regimen (non-
yeloablative vs. myeloablative), disease status (low or
ntermediate versus high risk), age of recipients (50
ears versus 50 years), sex mismatch between recip-
ent and donor (female donors/male recipients versus
thers), aGVHD (no or grade one versus grades II-
V), cGVHD (no versus yes). P-values of .05 were
onsidered signiﬁcant. The statistical analyses were
erformed using the SPSS/PC software, version
3.0 (Chicago, IL).ESULTS
eripheral Blood Stem Cell Collection,
ryopreservation, and Infusion after Thawing
PBSC collections to harvest CD34 cells over 4.0
06/kg were completed on 1 (n 90, 86%), 2 (n 12,
1%), or 3 consecutive days (n  3, 3%). A median of
.99  1010 TNCs was stored per bag in a median
olume of 117 mL. The median volumes of PBSCs
nfused amounted to 357 mL, ranging from 201 to 709
L in a median number of 3 bags (range 2-8 bags) per
atient. The median length of cryopreservation be-
ween collection and thawing was 15 days (range:
-238 days). The median viability of cells after thaw-
ng was 71.2%  1.0% (range: 50% to 98%). The
edian respective number of viable TNC and CD34
ells transplanted was 8.9  108/kg and 4.8  106/kg.
s determined after thawing, the grafts contained
FU-GM, BFU-E, CFU-MEG, and CFU-GEMM
t a frequency of 118, 134, 19, and 8.4  104/kg,
espectively. All infused PBSC products were micro-
iologically negative before cryopreservation and after
hawing.
The most common side effects encountered dur-
ng the infusion included nausea and vomiting [5],
ollowed by abdominal pain, bradycardia, hypoten-
ion, and chest tightness (Table 2). In general, the
ymptoms were rated at a toxicity grade of 1 or 2.
nly 1 patient experienced grade 3 toxicity with nau-
ea and vomiting. The following factors were found to
e associated with infusion related toxicities: (1) nau-
ea of any grade was more frequently observed in
emale patients (53.5%, 23 of 43 patients) compared
o male recipients (30.9%, 17 of 55 patients; P .025,
dds ratio [OR] 2.571 [1.123-5.885]). (2) Hypotension
P  .049, OR 1.219 [1.001-1.483]), and bradycardia
P  .048, OR 1.077 [1.001-1.159]), were asssociated
ith the total volume of infused DMSO per patient.
omparison of the Transplant Outcomes between
ryopreserved and Fresh PBSCT
The median follow-up of survivors after cryopre-
erved and fresh PBSCT was 411 days (range: 56-1346
able 2. Infusion-Related Toxicities of Thawed PBSC
Type of
Toxicity
Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
ausea/vomiting 24 (24.5) 15 (15.3) 1 (1.0)
bdominal pain 18 (18.4) 3 (3.1) 0 (0)
ypotension 1 (1.0) 2 (2.0) 0 (0)
radycardia 4 (4.1) 2 (2.0) 0 (0)
hest tightness 2 (2.0) 0 (0) 0 (0)
hills/Fever 0 (0) 0 (0) 0 (0)
eurologic signs 0 (0) 0 (0) 0 (0)
raded by common toxicity criteria, version 2.0 proposed by the
National Cancer Institute (available at http://ctep.cancer.gov/
forms/CTCv20_4-30-992.pdf).
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Allogeneic PBSCT with Cryopreserved Grafts 1237ays) and 1192 days (range: 800-1809 days), respec-
ively. Both groups showed similar engraftment kinet-
cs. The median time to reach neutrophil counts of
0.5  109/L was 17 and 18 days for recipients of
ryopreserved and fresh PBSCT (P .446; Figure 1A)
nd 21 days for neutrophils 1.0  109/L. Both
roups achieved a platelet count of 20  109/L after
3.0 days (P  .785; Figure 1B) and required similar
ime intervals to increase their platelet counts to over
0 109/L (15 days versus 16 days, P .858) or 100
09/L (22 days versus 22 days, P  .563).
Overall, 6 patients did not achieve engraftment
ntil the latest observation time point, including 1
ase receiving cryopreserved PBSCT and 5 cases re-
eiving fresh PBSCT. As shown in Table 3, 3 cases
ut of 6 cases (50%) were 1 antigen mismatched trans-
lants and 4 cases (67%) developed veno-occlussive
isease (VOD) of liver, which might be of signiﬁcant
ontribution to the development of engraftment fail-
re. However, their transplant doses of CD34 cells
r PBSC collection times were not different from
igure 1. Engraftment kinetics of neutrophils (A), platelets (B), and
erial recoveries of lymphocyte counts after cryopreserved and freshose of the overall group. rThe median number of days to achieve lympho-
yte counts above 0.5  109/L was 22 days for each
roup (P  .703), that above 1.0  109/L was 33 days
or each group (P .425), and that above 2.0  109/L
as 257 and 279 days (P  .687), respectively (Figure
C). Serial measurements of lymphocytes after allo-
eneic PBSCT revealed a gradual increase in their
requency from 1 month to 9 months, followed by a
lateau. The recovery kinetics after transplantation of
ryopreserved or fresh PBSC were not different as
etermined by a general linear model based on serial
ata (P  .926; Figure 1D).
The cumulative incidence of aGVHD grades
I-IV was 78.2% 4.3% after cryopreserved and 81.2%
4.5% after fresh PBSCT (P  .113; Figure 2A).
he respective cumulative incidence of cGVHD at 1
ear amounted to 83.8%  5.1% and 90.6%  3.4%
P  .673; Figure 2B). The OS rates at 1 and 2 years
or recipients of cryopreserved PBSCT were 64.3%
.1% and 52.7%  6.5% compared to 65.1%  4.6%
nd 59.4%  4.8% for the group of patients that had
ocytes (C) after cryopreserved and fresh PBSCT. D, Shows similar
T.lympheceived a fresh PBSCT (P  .668, Figure 3A). The
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D. H. Kim et al.1238RM and relapse rates were not signiﬁcantly different
n both groups. The respective 1-year NRM rates
ere 24.6%  4.6% and 20.4%  4.2% (P  .340;
igure 3B ), with a 2-year relapse rate of 26.6% 
.8% and 19.4%  4.3% (P  .295; Figure 3C).
able 3. Summary of Cases Failing Engraftment
Source of
PBSC Sex/Age Disease Conditioning
CD3
Cel
Cryo F/19 CML, 2nd BMT BUCY 5.3
Fresh M/45 Ph ALL CY/TBI 5.0
Fresh F/52 CLL CY/TBI 4.7
Fresh M/58 AML CY/TBI 5.2
Fresh F/56 AML CAT 2.7
Fresh F/57 NHL BUCY 3.9
BSC indicates peripheral blood stem cells; cryo, cryopreserved; C
ALL, acute lymphoblastic leukemia; CLL, chronic lymphocy
lymphoma; CY/TBI, Cyclophosphamide 60 mg/lg/day  2 day
amide 60 mg/kg/day 2 days, AraC 100 mg/m2/day for 5 days a
plus Cyclophosphamide 60 mg/kg/day  2 days; HLA, human
uremic syndrome/thrombocy thrombocytopenic purpura; GVH
106/kg of recipients body weight.
igure 2. Incidence of acute (A) and cGVHD (B) after cryopre-
ferved and fresh PBSCT.tem Cell Loss after Cryopreservation
The viability assessment of TNCs by trypan blue
xclusion yielded a median recovery of 71.2% 1.0%
fter thawing. The recovery rates ranged from 53% to
8%. Clonogenic hematopoietic progenitors were
valuated in cell culture before and after cryopreser-
ation to determine the relevance of trypan blue data
or this subset of cells (Figure 4). The loss of
FU-GM (24.6%  2.5%), BFU-E (30.5%  2.5%),
nd CFU-GEMM (21.3%  2.1%) was similar to
alculated values based on trypan blue exclusion. In
ontrast, the recovery of CFU-MEG as determined by
ulture studies was signiﬁcantly lower than calculated
alues (61.4%  3.1% versus 28.8%  1.0%; P 
001 by paired t-test).
orrelation of Clonogenic Progenitors with
D34 Cells and Total Nucleated Cells
The number of transplanted CD34 cells was
enerally well correlated with the frequency of trans-
lanted clonogenic progenitors including CFU-GM
r  0.666, P  .001), BFU-E (r  0.670, P  .001),
FU-MEG (r  0.478, P  .001), and CFU-GEMM
r  0.052, P .052) (Table 4). In contrast, the number
f transplanted TNCs was neither correlated with
D34 cells (P  .511) nor with clonogenic pregeni-
ors except for CFU-GEMM (r  0.438, P  .001).
actors Affecting Engraftment after
llogeneic PBSCT
Four of the 105 recipients of cryopreserved PBSCT
ailed to show engraftment of neutrophils. All 4 suf-
ered from severe infections: pneumonia (n  1),
epatosplenic candidiasis (n  1), necrotizing fasciitis
n  1), and Escherichia coli sepsis (n  1). The re-
aining 101 patients reached neutrophil levels of
1.0  109/L with a median of 21 days. Patients
eceiving a higher number of either cryopreserved or
ime(s) of
ollection Donor HLA Match Events Status
1 Sibling 6/6 VODHUS/TTP A60
1 Daughter 9/10 VOD D26
3 Sibling 9/10 VOD D34
1 Nephew 9/10 GVHDInfection D39
1 Sibling 6/6 Recurrence D290
1 Sibling 6/6 VOD D27
ronic myelogenous leukemia; BMT, bone marrow transplantation;
emia; AML, acute myelogenous leukemia; NHL, non-Hodgkin
otal body irradiation 1200 cGy, fractionated; CAT, Cyclophosph-
l body irradiation 500 cGy; BUCY, Busulfan 4 mg/kg/day 4 days
yte antigen; VOD, veno-occlussive disease; HUS/TTP, hemolytic
ft-versus-host disease; A, alive; D, death.4
ls*
T
C
ML, ch
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s and t
nd tota
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D, graresh CD34 cells engrafted their neutrophils faster
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Allogeneic PBSCT with Cryopreserved Grafts 1239han patients with lower cell doses when treating the
umber of CD34 cells as a continuous (P  .003) or
ategoric variable below and above the median (16
ays versus 18 days, P  .015). For both measures of
eutrophil engraftment (0.5 or1.0 109/L), there
as no association with the transplanted dose of
NCs (P  .880 and .685), CFU-GM (P  .985 and
560), BFU-E (P  .539 and .663), CFU-MEG (P 
igure 3. Overall survival, nonrelapse mortality, and recurrence
ates of patients receiving cryopreserved or freshly procured
llografts.297 and .087), or CFU-GEMM (P  .805 and .619). yOne (1%), 6 (6%), and 16 patients (15%) did not
each a platelet count over 20, 50, and 100  109/L,
espectively. The median number of days to achieve
hese counts was 13.0, 15.0, and 21.0 days. Patients
eceiving a higher CD34 cell dose increased their
latelet count more rapidly. Patients receiving a
igher number of CD34 cells engrafted their plate-
ets above 100  109/L faster than patients with
ower cell doses when treating the number of CD34
ells as a categoric variable below and above the me-
ian (18 days versus 28 days, P  .005).
To analyze the inﬂuence of the transplanted dose
f CFU-MEG on the platelet engraftment, patients
ere grouped in quartiles based on the transplanted
ose of CFU-MEG. The time to achieve a platelet
ount of over 20 or 50  109/L was similar in all 4
roups independent of using cryopreserved or fresh
BSCs. The time to reach a platelet count of over 100
09/L was not different in all 4 groups when analyzed
n overall patients or in the group receiving fresh
BSCT. However, the time to reach platelet counts
ver 100  109/L after transplantation of cryopre-
erved PBSC was slow for patients receiving a dose of
FU-MEG in the lowest quartile compared to the
atients with the other 3 quartiles of CFU-MEG
oses (median day 29 versus 18 days, P  .046). In
ddition, lower proportion of patients in this subgroup
chieved a platelet count of over 100  109/L (67%
ersus 89%).
valuation of Cryopreservation as a Risk Factor
or OS, NRM, and Disease Recurrence
A uni- and multivariate analysis using a Cox’s
roportional hazard model was performed to evaluate
he contribution of cryopreservation on OS, NRM,
nd recurrence in the context of a number of clinically
elevant parameters. The data are shown in Table 5.
he development of cGvHD inﬂuenced positively all
clinical outcomes. In addition, older age was associ-
ted with poorer OS and increased NRM. Patients
ith high-risk disease experienced reduced OS and
ncreased relapse rates. None of the outcome mea-
ures was inﬂuenced by cryopreservation.
ISCUSSION
The marrow repopulating ability of hematopoietic
rogenitor cells is sustained after cryopreservation.
raft cryopreservation technology is the cornerstone
f autologous transplantation and has facilitated the
evelopment of umbilical cord blood banking. The
xperience with cryopreserved allografts outside of
ord blood transplants is limited and restricted to
arrow as a source of repopulating cells [13,16]. A
eries using cryopreserved allogeneic PBSC has not
et been published. In part, the reluctance to use
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D. H. Kim et al.1240ryopreserved allografts is based on concerns that the
rocedure may alter viability and function of various
ellular subsets that might negatively inﬂuence graft
unction. Speciﬁcally, the question is raised as to
hether or not potential alterations of lymphoid sub-
ets may reduce the antimalignancy effect of the allo-
raft. In addition, the use of DMSO as cryoprotectant
ay result in toxicities that are not encountered with
he use of fresh allografts [1-4].
These issues were addressed in our current study
omparing the outcome of 2 consecutive cohorts of
atients transplanted with either cryopreserved or
reshly collected PBSCs. The cohorts did not differ in
ngraftment kinetics including lymphocyte recovery,
S, NRM, recurrence, aGVHD, and cGVHD. We
ere able to demonstrate that (1) there was no delay in
ngraftment of neutrophils and platelets, especially in
erms of long-term platelet engraftment beyond 100 
09/L. (2) The infusion-related toxicity was accept-
igure 4. Frequency of clonogenic hematopoietic progenitors in PB
fter 14 days’ incubation of 5  104 TNCs. Abbreviations: CFU-GM
nits erythroid; CFU-MEG, colony-forming units megakaryocyte;
egakaryocyte.
able 4. Correlation of Transplanted Doses of TNCs, CD34 Cells, an
Cell Type TNCs CD34 Cells
NCs indicates total nucleated cells; CFU-GM, colony-forming
CFU-MEG, colony-forming units megakaryocyte; CFU-GEM
cyte.ble: 99%, grade 2. Based on our data, the DMSO
olume infused per patient appears to be associated
ith cardiovascular adverse events such as hypoten-
ion or bradycardia [5,8]. (3) All 105 cryopreserved
llografts were free from bacterial contamination
16,30,31]. (4) The frequency of PBSC collections was
cceptable, because 97% of all donors required only 1
r 2 procedures [16].
The use of cryopreserved allografts is associated
ith beneﬁts. As discussed in a review article by Frey
t al. [16], it provides the following opportunities: (1)
reater ﬂexibility to schedule collections and trans-
lants, (2) evaluation of the quality of grafts particu-
arly prior to initiating myeloablative preparation of
he respective recipient, (3) rescheduling of collections
n the event of poor mobilization and potential use of
ifferent mobilization strategies such as administra-
ion of AMD 3100 [32,33] or the use of different
onors, and (4) collection and cryopreservation of
paration before cryopreservation and after thawing. Colony counts
ny-forming units granulocyte-macrophage; BFU-E, Burst-forming
EMM, colony-forming units granulocyte-erythrocyte-monocyte-
genic Hematopoietic Precursors
elation Coefficient (R)
M BFU-E CFU-MEG CFU-GEMM
granulocyte-macrophage; BFU-E, Burst-forming units erythroid;
ony-forming units granulocyte-erythrocyte-monocyte-megakaryo-SC pre
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Allogeneic PBSCT with Cryopreserved Grafts 1241ufﬁcient cells for multiple infusion of DLIs through a
ingle procedure.
Our data on PBSCT are largely consistent with
revious studies comparing cryopreserved and fresh
one marrow [14]. Similar engraftment kinetics of
eutrophils and platelets, as well as the day 100 sur-
ival were reported [14,34]. There was some discrep-
ncy with respect to published data for aGVHD.
tockschlader et al. [14] reported a similar incidence
f grade II-IV aGVHD for both recipients of fresh
nd cryopreserved marrow compared to a lower inci-
ence observed for recipients of cryopreserved mar-
ow by Eckardt et al. [34]. As mentioned above, sim-
lar rates of aGVHD (P  .113) and cGVHD (P 
673), as well as recurrence, were observed for both
ohorts receiving PBSCT, suggesting that cryopreser-
ation does not selectively alter graft function includ-
ng the graft-versus-malignancy effect. This view is
upported by a similar lymphocyte count recovery
n both cohorts. Future studies should include the
etermination of more detailed functional proﬁles
f the emerging lymphocyte populations such as
ow cytometric proﬁling, T cell receptor rearrange-
ent excision circles (TRECs), CD3R spectratyp-
ng, or ELISA/ELISPOT assays [35].
The rates of aGVHD and cGVHD were relatively
igh in both patient cohorts. One may speculate
hat this observation results from the relatively old
able 5. Uni- and Multivariate Analyses to Evaluate the Contribution
nd Disease Recurrence
Prognostic Factor
Univar
P-Value
verall Survival
Cryopreservation .768 1.
Myeloablative conditioning .103 1.
High risk disease .030 2.
Older age (>50 years) .015 1.
Female donor/male recipient .824 0.
Acute GVHD, grade 2-4 .833 0.
Chronic GVHD <.001 0.
on-relapse mortality
Cryopreservation .342 1.
Myeloablative conditioning .841 1.
High-risk disease .439 0.
Older age (>50 years) .020 2.
Female donor/male recipient .745 1.
Acute GVHD, grade 2-4 .091 2.
Chronic GVHD .021 0.
ecurrence
Cryopreservation .297 1.
Myeloablative conditioning .008 0.
High risk disease <.001 8.
Older age (>50 years) .111 1.
Female donor/male recipient .146 0.
Acute GVHD, grade 2-4 .094 0.
Chronic GVHD <.001 0.
VHD indicates graft-versus-host disease; HR, hazard ratio; 95%atient population (median age, 50 years) and the lse of PBSC as a source of stem cells. In addition,
0% of donors were 1 antigen mismatched donors,
hich might also contribute to a higher incidence of
VHD.
The possibility that cryopreservation may inﬂu-
nce cell populations present at low concentrations,
owever, should at least be considered. In our study,
ttention was drawn to this possibility by differences
n the survival of CFU-MEGs, indicating their in-
reased sensitivity to cold damage compared to other
lonogenic progenitors [36].
In summary, although not randomized, the pre-
ented study on 105 prospectively studied recipients of
ryopreserved allogeneic PBSC and 106 historic con-
rols that had received fresh allogeneic PBSC, sug-
ests that cryopreserved allografts are not inferior to
reshly collected preparations. Side effects related to
he collection and infusion are generally of limited
everity and clinical outcomes including engraftment
inetics, OS, NRM, aGVHD, cGvHD, and recur-
ence rates are similar.
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